Canvas Wealth Advisors LLC increased its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 170.2% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,394 shares of the medical research company's stock after acquiring an additional 878 shares during the quarter. Canvas Wealth Advisors LLC's holdings in Thermo Fisher Scientific were worth $565,000 at the end of the most recent quarter.
A number of other hedge funds have also modified their holdings of TMO. CBIZ Investment Advisory Services LLC raised its stake in Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock valued at $28,000 after purchasing an additional 33 shares in the last quarter. Anderson Financial Strategies LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter valued at about $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the 1st quarter worth about $31,000. IMA Advisory Services Inc. purchased a new stake in shares of Thermo Fisher Scientific in the first quarter valued at approximately $35,000. Finally, Smallwood Wealth Investment Management LLC bought a new position in Thermo Fisher Scientific in the first quarter worth approximately $37,000. 89.23% of the stock is currently owned by institutional investors.
Thermo Fisher Scientific Stock Up 0.4%
Shares of NYSE:TMO opened at $539.05 on Monday. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65. The firm has a 50 day simple moving average of $495.74 and a 200-day simple moving average of $448.98. The company has a market capitalization of $203.55 billion, a PE ratio of 31.18, a P/E/G ratio of 2.93 and a beta of 0.77. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97.
Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping the consensus estimate of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the company posted $5.37 earnings per share. The firm's revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.
Analyst Ratings Changes
Several research firms have recently commented on TMO. UBS Group boosted their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research report on Thursday, July 24th. Wall Street Zen downgraded shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, October 12th. Barclays raised their price target on shares of Thermo Fisher Scientific from $550.00 to $585.00 and gave the stock an "overweight" rating in a report on Thursday, October 2nd. William Blair initiated coverage on Thermo Fisher Scientific in a research report on Monday, August 18th. They issued an "outperform" rating on the stock. Finally, Redburn Partners set a $580.00 price objective on Thermo Fisher Scientific in a report on Wednesday, October 8th. Fifteen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $589.10.
Read Our Latest Stock Report on TMO
Insiders Place Their Bets
In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares in the company, valued at $10,735,712.66. This represents a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Joseph R. Holmes sold 385 shares of the company's stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 30,066 shares of company stock worth $14,182,963. Insiders own 0.33% of the company's stock.
About Thermo Fisher Scientific
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Read More
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.